

Attorney Docket No. UAB-15402/22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jay M. Meythaler et al.

Serial No.: 10/049,328

Group Art Unit: 1614

Filing Date: May 15, 2002

Examiner: Donna A. Jagoe

For: USE OF GABA AGONISTS FOR TREATMENT OF SPASTIC
DISORDERS, CONVULSIONS, AND EPILEPSY

STATEMENT OF THE SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Please enter the following statement of record of interview with regard to the above-referenced application. Applicant hereby provides the following information with respect to the telephonic interview of June 28, 2007 between Examiner Jagoe, SPE Marschel, and Applicant's representative, Avery Goldstein. No demonstrations were performed. The interview included a discussion of claim 12 and Applicant's efforts to explicitly exclude 4-chlorophenyl-5-fluoro-2-hydroxyphenylmethanone from the claim. Applicant reiterated that administration of GABAamide precludes the side effects associated with the 4-chlorophenyl-5-fluoro-2-hydroxyphenylmethanone metabolite of progabide. No agreement was asked for and as such is inapplicable. The substance of this interview is incorporated in the RCE filed in July 2007.

Applicant believes the above summary is in compliance with 37 CFR 1.133. Entry of this summary is hereby requested.

Respectfully submitted,

Dated: 7-23-07

/Avery Goldstein/
Avery Goldstein
Registration No. 39,204
Gifford, Krass, Groh, Sprinkle,
Anderson & Citkowski, P.C.
2701 Troy Center Drive, Suite 330
P.O. Box 7021
Troy, MI 48007-7021
(248) 647-6000

Attorney for Applicant

ANG